SARS-CoV-2 lineage B.1.617

Cocrystal Pharma’s SARS-CoV-2 3CL Protease Lead CDI-45205 Demonstrates Broad-Spectrum Activity Against the SARS-CoV-2 Delta and Gamma Variants

Retrieved on: 
Thursday, July 29, 2021
Coronaviridae, Variants of SARS-CoV-2, Sarbecovirus, Zoonoses, Severe acute respiratory syndrome coronavirus 2, 3C-like protease, SARS-CoV-2 lineage B.1.617, SARS-CoV-2 Beta variant, SARS-CoV-2 Delta variant, Middle East respiratory syndrome–related coronavirus, COVID-20

BOTHELL, Wash., July 29, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces that its SARS-CoV-2 3CL protease lead CDI-45205 and several analogs showed potent in vitro activity against the SARS-CoV-2 Delta (India/B.1.617.2) and Gamma (Brazil/P.1) variants.

Key Points: 
  • BOTHELL, Wash., July 29, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces that its SARS-CoV-2 3CL protease lead CDI-45205 and several analogs showed potent in vitro activity against the SARS-CoV-2 Delta (India/B.1.617.2) and Gamma (Brazil/P.1) variants.
  • Cocrystal previously announced that CDI-45205 and analogs exhibited broad-spectrum activity against the SARS-CoV-2 Alpha (United Kingdom/B.1.1.7) and Beta (South African/B.1.351) variants, surpassing the activity observed with the Wuhan strain.
  • The broad-spectrum activity against these SARS-CoV-2 variants is highly encouraging as CDI-45205 previously demonstrated excellent in vivo efficacy in a MERS-CoV-2 infected animal model.
  • The Company continues to develop SARS-CoV-2 oral protease inhibitors and replication inhibitors using its proprietary drug discovery platform technology.

New Publications Confirm Paragon Genomics CleanPlex® SARS-CoV-2 Panel Enables Accurate Identification of Variants of Concern

Retrieved on: 
Wednesday, July 28, 2021
Coronaviridae, Variants of SARS-CoV-2, Sarbecovirus, COVID-19 pandemic in India, COVID-19, SARS-CoV-2 lineage B.1.617, Severe acute respiratory syndrome coronavirus 2, SARS-CoV-2 Alpha variant, SARS-CoV-2 Delta variant, Severe acute respiratory syndrome coronavirus, COVID-20

The analyses enabled the researchers to assign the viral genomes to SARS-CoV-2 lineages and confirm the presence of the B.1.1.7 variant.

Key Points: 
  • The analyses enabled the researchers to assign the viral genomes to SARS-CoV-2 lineages and confirm the presence of the B.1.1.7 variant.
  • A third study, from a Paragon Genomics public health laboratory customer, describes how the CleanPlex SARS-CoV-2 Panel enabled the early identification of one of the first confirmed cases of the B.1.617.2 Delta variant in Brazil.
  • Paragon Genomics' CleanPlex SARS-CoV-2 technology has powered variant detection and tracking since the virus first appeared.
  • In March 2020, the company launched the CleanPlex SARS-CoV-2 Panel whole genome SARS-CoV-2 sequencing on Illumina and MGI Tech sequencing platforms.

ImmunoPrecise's PolyTope™ TATX-03 Antibody Cocktail Potently Neutralizes SARS-CoV-2 Delta Variant in in vitro Pseudovirus Assays

Retrieved on: 
Thursday, July 22, 2021
Biotechnology, General Health, Infectious diseases, Health, Clinical trials, Variants of SARS-CoV-2, Coronaviridae, SARS-CoV-2, SARS-CoV-2 lineage B.1.617, SARS-CoV-2 Delta variant, Severe acute respiratory syndrome coronavirus 2, SARS-CoV-2 Kappa variant, SARS-CoV-2 Alpha variant, SARS-CoV-2 Beta variant, Variant of concern

As such, the Company continuously validates, and has demonstrated to date, maintained neutralization potency of IPAs multi-antibody cocktail towards SARS-CoV-2 variants of concern.

Key Points: 
  • As such, the Company continuously validates, and has demonstrated to date, maintained neutralization potency of IPAs multi-antibody cocktail towards SARS-CoV-2 variants of concern.
  • IPA previously announced that TATX-03 demonstrated strong efficacy in reducing viral load in vivo using a hamster challenge model and potently neutralized pseudovirus of Alpha (B.1.1.7) and Beta (B.1.351) variants in vitro.
  • Additional evaluation of virus neutralization potency in an in vitro pseudovirus-based assay revealed that IPAs TATX-03 anti-SARS-CoV-2 antibody cocktail is also not affected by the rapidly spreading Delta variant (B.1.617.2).
  • Parallel reactivity screening of the individual antibodies of TATX-03 revealed differential susceptibility of the lead components towards the Delta (B.1.617.1) variant with the majority showing maintained binding.

GT Molecular Launches Highly Sensitive PCR Tests for the SARS-CoV-2 Delta Variant and Influenza A/B

Retrieved on: 
Tuesday, July 13, 2021
Natural sciences, Laboratory techniques, Molecular biology, Branches of biology, Chemistry, Polymerase chain reaction, Variants of SARS-CoV-2, Biotechnology, Real-time polymerase chain reaction, SARS-CoV-2 lineage B.1.617, Digital polymerase chain reaction, SARS-CoV-2 Delta variant

FORT COLLINS, Colo., July 13, 2021 /PRNewswire/ --GT Molecular, an industry leader in wastewater testing and multiplex, ultrasensitive PCR assays for cancer and pathogen epidemiology, has started shipping its sensitive PCR tests to monitor the coronavirus Delta variant (B.1.617.2).

Key Points: 
  • FORT COLLINS, Colo., July 13, 2021 /PRNewswire/ --GT Molecular, an industry leader in wastewater testing and multiplex, ultrasensitive PCR assays for cancer and pathogen epidemiology, has started shipping its sensitive PCR tests to monitor the coronavirus Delta variant (B.1.617.2).
  • Delta/Epsilon Digital PCR or RT-qPCR Stand-alone kits differentiate SARS-CoV-2 Epsilon variant and the family of variants first identified in India (B.1.617 group), including the Delta variant.
  • Influenza A/B digital PCR Stand-alone kit detects and differentiates Influenza A and B.
  • GT Molecular is a leader in providing highly customizable, ultrasensitive digital PCR and qPCR tests and services.

Seegene Introduces New SARS-CoV-2 Variants Detection Test That Can Screen Six Virus Variants Including the Delta and Delta Plus

Retrieved on: 
Tuesday, July 13, 2021
Coronaviridae, Variants of SARS-CoV-2, COVID-19, Sarbecovirus, Zoonoses, Severe acute respiratory syndrome coronavirus 2, Severe acute respiratory syndrome, SARS-CoV-2 lineage B.1.617, SARS-CoV-2 Zeta variant

Seegene launches new multiplex PCR test capable of screening six SARS-CoV-2 variants including the Delta and Delta Plus variants attributable for a recent surge in global COVID-19 cases.

Key Points: 
  • Seegene launches new multiplex PCR test capable of screening six SARS-CoV-2 variants including the Delta and Delta Plus variants attributable for a recent surge in global COVID-19 cases.
  • In a single reaction, the variants diagnostic kit identifies a total of six COVID-19 variants that are known to be originated from India such as Delta, Delta Plus, and Kappa, and Gamma(Brazil), Beta(South Africa), and Epsilon(California).
  • Seegene also said that it has successfully developed a research-use-only diagnostic tests, 'Allplex SARS-CoV-2/P681R Assay,' to precisely target the Delta and Delta Plus variants.
  • According to Seegene, the combination use of its two assays including 'Allplex SARS-CoV-2 Variants II Assay' and the 'Allplex SARS-CoV-2 Variants I Assay' can screen almost all existing COVID-19 variants.

Seegene Introduces New SARS-CoV-2 Variants Detection Test That Can Screen Six Virus Variants Including the Delta and Delta Plus

Retrieved on: 
Tuesday, July 13, 2021
Coronaviridae, Variants of SARS-CoV-2, COVID-19, Sarbecovirus, Zoonoses, Severe acute respiratory syndrome coronavirus 2, Severe acute respiratory syndrome, SARS-CoV-2 lineage B.1.617, SARS-CoV-2 Zeta variant

Seegene launches new multiplex PCR test capable of screening six SARS-CoV-2 variants including the Delta and Delta Plus variants attributable for a recent surge in global COVID-19 cases.

Key Points: 
  • Seegene launches new multiplex PCR test capable of screening six SARS-CoV-2 variants including the Delta and Delta Plus variants attributable for a recent surge in global COVID-19 cases.
  • In a single reaction, the variants diagnostic kit identifies a total of six COVID-19 variants that are known to be originated from India such as Delta, Delta Plus, and Kappa, and Gamma(Brazil), Beta(South Africa), and Epsilon(California).
  • Seegene also said that it has successfully developed a research-use-only diagnostic tests, 'Allplex SARS-CoV-2/P681R Assay,' to precisely target the Delta and Delta Plus variants.
  • According to Seegene, the combination use of its two assays including 'Allplex SARS-CoV-2 Variants II Assay' and the 'Allplex SARS-CoV-2 Variants I Assay' can screen almost all existing COVID-19 variants.

Therma Bright's AcuVid(TM) COVID-19 Rapid Antigen Saliva Test Successfully Detects the COVID-19 Delta Variant Strain

Retrieved on: 
Thursday, July 8, 2021
Coronaviridae, Variants of SARS-CoV-2, Zoonoses, COVID-19, SARS-CoV-2 lineage B.1.617, SARS-CoV-2 Delta variant, Severe acute respiratory syndrome coronavirus 2

Toronto, Ontario--(Newsfile Corp. - July 8, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of its smart-enabled AcuVid COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce the completion and validation that its AcuVid COVID-19 Rapid Antigen Saliva Test successfully detected the highly contagious, fast moving COVID-19 Delta B.1.617.2 variant.

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - July 8, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of its smart-enabled AcuVid COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce the completion and validation that its AcuVid COVID-19 Rapid Antigen Saliva Test successfully detected the highly contagious, fast moving COVID-19 Delta B.1.617.2 variant.
  • The Delta variant is becoming the fastest moving, most dominant COVID-19 strain globally; on June 24th Therma Bright and its partners announced and initiated the Delta variant study.
  • The study focused on ensuring the Company's AcuVid COVID-19 Rapid Antigen Saliva Test would successfully perform and easily detect the ever-growing list of mutations from the original Wuhan SARS-CoV-2 Novel Coronavirus.
  • Sources: Delta variant news coverage as becoming the dominant COVID-19 variant in US, UK, Europe, India and Africa